Fradafiban hydrochloride

• CAT Number: I041383
• Molecular Formula: C20H22ClN3O4
• Molecular Weight: 403.86
• Purity: ≥95%
• Synonyms: 2-[(3S,5S)-5-[[4-(4-carbamimidoylphenyl)phenoxy]methyl]-2-oxopyrrolidin-3-yl]acetic acid;hydrochloride
• InChI: InChI=1S/C20H21N3O4.ClH/c21-19(22)14-3-1-12(2-4-14)13-5-7-17(8-6-13)27-11-16-9-15(10-18(24)25)20(26)23-16;/h1-8,15-16H,9-11H2,(H3,21,22)(H,23,26)(H,24,25);1H/t15-,16-;/m0./s1
• InChIKey: IUCGFVXOLDQDRV-MOGJOVFKSA-N
• SMILES: C1[C@H](C(=O)N[C@@H]1COC2=CC=C(C=C2)C3=CC=C(C=C3)C(=N)N)CC(=O)O.Cl

Fradafiban hydrochloride（Cat No.:I041383）is an investigational small molecule that acts as a selective inhibitor of the integrin αIIbβ3, a key receptor involved in platelet aggregation and blood clot formation. By blocking this receptor, Fradafiban hydrochloride prevents platelet activation and aggregation, making it a potential therapeutic candidate for treating thrombotic disorders, such as acute coronary syndrome, stroke, and other cardiovascular conditions. Its hydrochloride form improves solubility and stability, facilitating its use in clinical trials. Research continues to explore its efficacy and safety profile in the prevention and treatment of thromboembolic events.